Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine

Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156 · see citing works

Glutamate uptake

Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,068 · see citing works

Implications of Normal Brain Development for the Pathogenesis of Schizophrenia

Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724 · see citing works

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses

Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · see citing works

Recent advances in the phencyclidine model of schizophrenia

(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · see citing works

Antipsychotic-induced weight gain: a comprehensive research synthesis

Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · see citing works

Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia

Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D. A., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,374 · see citing works

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220 · see citing works

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

Tol, H. H. M. V., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P. M., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,015 · see citing works

Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex

Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · see citing works

Glutamate receptor dysfunction and schizophrenia

Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · see citing works

Antipsychotic drug doses and neuroleptic/dopamine receptors

SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622 · see citing works

Modulation of memory fields by dopamine Dl receptors in prefrontal cortex

Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593 · see citing works

Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative

Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428 · see citing works

Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine

Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,420 · see citing works

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352 · see citing works

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,347 · see citing works

Risperidone in the treatment of schizophrenia

Marder, S. R., & Meibach, R. C. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,194 · see citing works

Cannabis and schizophrenia. A longitudinal study of Swedish conscripts

Andréasson, S., Engström, A., Allebeck, P., & Rydberg, U. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92620-1 · Cited by 1,166 · see citing works

Does Fast Dissociation From the Dopamine D ₂ Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis

Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140 · see citing works

Relationship Between Dopamine D ₂ Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090 · see citing works

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

Geddes, J. R., Freemantle, N., Harrison, P. J., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,060 · see citing works

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,035 · see citing works

Antischizophrenic Drugs: Chronic Treatment Elevates Dopamine Receptor Binding in Brain

Burt, D. R., Creese, I., & Snyder, S. H. (1977) · Science · doi:10.1126/science.847477 · Cited by 1,027 · see citing works

The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia

Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,022 · see citing works

Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats

Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006 · see citing works

Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

Shapiro, D. A., Renock, S. M., Arrington, E. G., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. B. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 971 · see citing works

Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

Burris, K. D., Molski, T. F. P., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 924 · see citing works

The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia

GOFF, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 914 · see citing works

Atypical antipsychotics: Mechanism of action

Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899 · see citing works

Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex

Mirnics, K., Middleton, F. A., Marquez, A., Lewis, D. A., & Levitt, P. (2000) · Neuron · doi:10.1016/s0896-6273(00)00085-4 · Cited by 882 · see citing works

Dopamine receptors and the dopamine hypothesis of schizophrenia

Seeman, P. M. (1987) · Synapse · doi:10.1002/syn.890010203 · Cited by 880 · see citing works

A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment.

Flores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B., & Kellar, K. J. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08832-7 · Cited by 880 · see citing works

Catechol- <i>O</i> -methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior

Gogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864 · see citing works

D1 receptors in prefrontal cells and circuits

Goldman-Rakic, P. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00045-4 · Cited by 807 · see citing works

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

Leucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795 · see citing works

The Effects of Risperidone on the Five Dimensions of Schizophrenia Derived by Factor Analysis

Marder, S. R., Davis, J. M., & Chouinard, G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1205 · Cited by 761 · see citing works

Prefrontal neurons and the genetics of schizophrenia

Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., Berman, K. F., & Goldberg, T. E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01252-5 · Cited by 744 · see citing works

Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia

Kapur, S., Zipursky, R. B., & Remington, G. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 711 · see citing works

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET

Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., et al. (1997) · Nature · doi:10.1038/385634a0 · Cited by 710 · see citing works

Schizophrenia, sensory gating, and nicotinic receptors

Adler, L. E., Olincy, A., Waldo, M., Harris, J. G., Griffith, J., Stevens, K., Flach, K., Nagamoto, H., Bickford, P., Leonard, S., et al. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033320 · Cited by 690 · see citing works

The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysis

Keefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033374 · Cited by 690 · see citing works

Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

Bodick, N. C., Offen, W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 687 · see citing works

Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons

Chiodo, L. A., & Bunney, B. (1983) · Journal of Neuroscience · doi:10.1523/jneurosci.03-08-01607.1983 · Cited by 680 · see citing works

NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers

Malhotra, A. K. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680 · see citing works

D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia

Tsai, G. E., Yang, P., Chang, Y., & Chong, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 676 · see citing works

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Stroup, T., Mcevoy, J., Swartz, M., Byerly, M., Glick, I., Cañive, J., McGee, M., Simpson, G., Stevens, M., & Lieberman, J. (2003) · Schizophrenia bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 647 · see citing works

Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials

Chakos, M., Lieberman, J. A., Hoffman, E. B., Bradford, D. W., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 632 · see citing works

Dopamine D4 receptors elevated in schizophrenia

Seeman, P. M., Guan, H., & Tol, H. H. M. V. (1993) · Nature · doi:10.1038/365441a0 · Cited by 627 · see citing works

Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder

Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., ZIMBROFF, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624 · see citing works

Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment

Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 617 · see citing works

Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder

Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M. W., Stock, E. G., Stringfellow, J., Ingenito, G. G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 592 · see citing works

Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons

White, F. J., & Wang, R. Y. (1983) · Science · doi:10.1126/science.6136093 · Cited by 590 · see citing works

Executive Subprocesses in Working Memory

Goldberg, T. E., Egan, M. F., Gscheidle, T., Coppola, R., Weickert, T. W., Kolachana, B. S., Goldman, D. A., & Weinberger, D. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.9.889 · Cited by 580 · see citing works

D-serine added to antipsychotics for the treatment of schizophrenia

Tsai, G. E., Yang, P., Chung, L.-C., LANGE, N. D., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 572 · see citing works

The Glutamatergic Dysfunction Hypothesis for Schizophrenia

Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · see citing works

Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys

Arnsten, A. F. T., Cai, J. X., Murphy, B. L., & Goldman-Rakic, P. S. (1994) · Psychopharmacology · doi:10.1007/bf02245056 · Cited by 566 · see citing works

Longitudinal study of brain morphology in first episode schizophrenia

Lieberman, J. A., Chakos, M., Wu, H., Alvir, J. M., Hoffman, E. B., Robinson, D. G., & Bilder, R. M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01067-8 · Cited by 554 · see citing works

Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity

Bunney, B. S., & Grace, A. A. (1978) · Life Sciences · doi:10.1016/0024-3205(78)90471-x · Cited by 553 · see citing works

α ₂ -Adrenergic Mechanisms in Prefrontal Cortex Associated with Cognitive Decline in Aged Nonhuman Primates

Arnsten, A. F. T., & Goldman-Rakic, P. S. (1985) · Science · doi:10.1126/science.2999977 · Cited by 549 · see citing works

Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo

Do, K. Q., Trabesinger, A. H., Kirsten‐Krüger, M., Lauer, C. J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P., & Cuénod, M. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00229.x · Cited by 540 · see citing works

Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder

Bilder, R. M., GOLDMAN, R. S., Volavka, J., Czobor, P., Hoptman, M. J., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538 · see citing works

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529 · see citing works

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients

Nordström, A., Farde, L., Wiesel, F., Forslund, K., Pauli, S., Halldin, C., & Uppfeldt, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90288-o · Cited by 527 · see citing works

Cognitive effects of nicotine

Rezvani, A. H., & Levin, E. D. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01094-5 · Cited by 519 · see citing works

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01532-7 · Cited by 512 · see citing works

5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release

Ichikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 495 · see citing works

Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia

Heresco‐Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G. S., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487 · see citing works

Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective

Lieberman, J. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00147-x · Cited by 486 · see citing works

Quetiapine in Patients With Schizophrenia

Small, J. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180067009 · Cited by 482 · see citing works

Neuropsychological Change in Early Phase Schizophrenia During 12 Months of Treatment With Olanzapine, Risperidone, or Haloperidol

Purdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 471 · see citing works

Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials

Leucht, S., Pitschel‐Walz, G., Engel, R. R., & Kissling, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.180 · Cited by 470 · see citing works

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

Marder, S. R., McQuade, R. D., Stock, E. G., Kaplita, S., Marcus, R. N., Safferman, A. Z., Saha, A. R., Ali, M. W., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467 · see citing works

The Contribution of α2-Noradrenergic Mechanisms to Prefrontal Cortical Cognitive Function: Potential Significance for Attention-Deficit Hyperactivity Disorder

Arnsten, A. F. T. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050084013 · Cited by 458 · see citing works

Synaptotagmins: C2-domain proteins that regulate membrane traffic.

Südhof, T., & Rizo, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80171-3 · Cited by 450 · see citing works

A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia

GOFF, D. C., Tsai, G. E., Levitt, J. J., AMICO, E. T., Manoach, D. S., Schoenfeld, D., Hayden, D. L., McCarley, R. W., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436 · see citing works

Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it

Flood, J. F., Morley, J. E., & Roberts, E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1567 · Cited by 436 · see citing works

Atypical antipsychotics and weightgain — a systematic review

Taylor, D. M., & McAskill, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101006416.x · Cited by 435 · see citing works

Elevated endogenous cannabinoids in schizophrenia

Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999) · Neuroreport · doi:10.1097/00001756-199906030-00008 · Cited by 431 · see citing works

Cognitive Effects of Nicotine

Sofouglu, M., Herman, A. I., Robinson, C. D., & Waters, A. J. (2014) · Lincoln (University of Nebraska) · Cited by 417 · see citing works

Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis

Kim, T., Tao-Cheng, J.-H., Eiden, L. E., & Loh, Y. P. (2001) · Cell · doi:10.1016/s0092-8674(01)00459-7 · Cited by 414 · see citing works

Modulation of N -methyl- d -aspartate receptor function by glycine transport

Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 412 · see citing works

Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes

Lawler, C. P. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00099-2 · Cited by 409 · see citing works

Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder

Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 408 · see citing works

Reversal of Antipsychotic-Induced Working Memory Deficits by Short-Term Dopamine D1 Receptor Stimulation

Castner, S. A., Williams, G. V., & Goldman, P. S. (2000) · Science · doi:10.1126/science.287.5460.2020 · Cited by 401 · see citing works

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

Green, M. F., Marshall, B. D., Wirshing, W. C., Ames, D., Marder, S. R., McGurk, S. R., Kern, R. S., & Mintz, J. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.799 · Cited by 397 · see citing works

A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy

Kapur, S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.553 · Cited by 396 · see citing works

The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes

Arnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391 · see citing works

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

Spohn, H. E., & Strauss, M. E. (1989) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.98.4.367 · Cited by 381 · see citing works

Neurochemical Characteristics of Amisulpride, an Atypical Dopamine D2/D3 Receptor Antagonist with Both Presynaptic and Limbic Selectivity

Schoemaker, H., Claustre, Y., Fage, D., Rouquier, L., Chergui, K., Curet, O., Oblin, A., Gonon, F., Carter, C. J., Bénavidès, J., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36395-5 · Cited by 371 · see citing works

5-HT₂and D₂Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation

Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370 · see citing works

Progressive Decrease of Left Superior Temporal Gyrus Gray Matter Volume in Patients With First-Episode Schizophrenia

Kasai, K., Shenton, M. E., Salisbury, D. F., Hirayasu, Y., Lee, C., Ciszewski, A. A., Yurgelun-Todd, D. A., Kikinis, R., Jolesz, F. A., & McCarley, R. W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.156 · Cited by 365 · see citing works

Amelioration of negative symptoms in schizophrenia by glycine

Javitt, D. C., Zylberman, I., Zukin, S. R., Heresco‐Levy, U., & Lindenmayer, J. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1234 · Cited by 353 · see citing works

Progressive Decrease of Left Heschl Gyrus and Planum Temporale Gray Matter Volume in First-Episode Schizophrenia

Kasai, K., Shenton, M. E., Salisbury, D. F., Hirayasu, Y., Onitsuka, T., Spencer, M. H., Yurgelun-Todd, D. A., Kikinis, R., Jolesz, F. A., & McCarley, R. W. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.8.766 · Cited by 352 · see citing works

Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains

Lee, T., Seeman, P. M., Tourtellotte, W. W., Farley, I. J., & HORNYKEIWICZ, O. (1978) · Nature · doi:10.1038/274897a0 · Cited by 351 · see citing works

Management of treatment resistance in schizophrenia

Conley, R. R., & Kelly, D. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01271-9 · Cited by 350 · see citing works

Pharmacogenetic prediction of clozapine response

Arranz, M. J., Munro, J., Birkett, J., Bolonna, A. A., Mancama, D. T., Sodhi, M., Lesch, K., Meyer, J., Sham, P. C., Collier, D. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02221-2 · Cited by 347 · see citing works

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

Nordström, A., Farde, L., Nyberg, S., Karlsson, P., Halldin, C., & Sedvall, G. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1444 · Cited by 339 · see citing works

Control of Serotonergic Function in Medial Prefrontal Cortex by Serotonin-2A Receptors through a Glutamate-Dependent Mechanism

Martín‐Ruiz, R., Puig, M. V., Celada, P., Shapiro, D. A., Roth, B. L., Mengod, G., & Artigas, F. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09856.2001 · Cited by 338 · see citing works

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease

Coyle, J. T., & Kershaw, P. R. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 337 · see citing works

Immunohistochemical localization of PDE10A in the rat brain

Seeger, T., Bartlett, B. L., Coskran, T., Culp, J. S., James, L. C., Krull, D., Lanfear, J., Ryan, A. M., Schmidt, C. J., Strick, C. A., et al. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02754-9 · Cited by 335 · see citing works

Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response.

Bakshi, V. P., Swerdlow, N. R., & Geyer, M. A. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23831-9 · Cited by 330 · see citing works

Free d-aspartate and d-serine in the mammalian brain and periphery

Hashimoto, A., & Oka, T. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00019-1 · Cited by 328 · see citing works

Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development

Compagnone, N. A., & Mellon, S. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4678 · Cited by 327 · see citing works

Expert Consensus Guideline Series Treatment of Schizophrenia 1999

Jp, M. (1999) · Medical Entomology and Zoology · Cited by 325 · see citing works

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary

Kane (2003) · The Journal of Clinical Psychiatry · Cited by 324 · see citing works

Introduction: Methods, Commentary, and Summary

Alexopoulos, G. S., Streim, J. E., Carpenter, D. P., & Docherty, J. P. (2004) · The Journal of Clinical Psychiatry · Cited by 316 · see citing works

The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential

Leeson, P. D., & Iversen, L. L. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00050a001 · Cited by 316 · see citing works

Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]Raclopride

Yokoi, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00304-4 · Cited by 315 · see citing works

Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex

Goldman-Rakic, P. S., Lidow, M. S., & Gallager, D. W. (1990) · Journal of Neuroscience · doi:10.1523/jneurosci.10-07-02125.1990 · Cited by 311 · see citing works

Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

Silvestri, S., Seeman, M. V., Negrete, J.-C., Houle, S., Shammi, C. M., Remington, G. J., Kapur, S., Zipursky, R. B., Wilson, A. A., Christensen, B. K., et al. (2000) · Psychopharmacology · doi:10.1007/s002130000532 · Cited by 311 · see citing works

Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia

Pigott, T. A., Carson, W. H., Saha, A. R., Torbeyns, A. F., Stock, E. G., Ingenito, G. G., & Aripiprazole Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0910 · Cited by 309 · see citing works

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

Kasper, S. F., Lerman, M. N., McQuade, R. D., Saha, A. R., Carson, W. H., Ali, M. W., Archibald, D., Ingenito, G. G., Marcus, R. N., & Pigott, T. A. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003651 · Cited by 309 · see citing works

Receptor pharmacology of neuroleptics: relation to clinical effects.

Richelson, E. (1999) · PubMed · Cited by 307 · see citing works

Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?

O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307 · see citing works

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

Tollefson, G. D., & Sanger, T. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.466 · Cited by 306 · see citing works

Allosteric Sensitization of Nicotinic Receptors by Galantamine, a New Treatment Strategy for Alzheimer’s Disease

Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303 · see citing works

Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

Seeman, P. M., & Tallerico, T. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000336 · Cited by 302 · see citing works

Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors

Bergeron, R., de Montigny, C., & Debonnel, G. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-03-01193.1996 · Cited by 299 · see citing works

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D. M., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., & Conn, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835612100 · Cited by 295 · see citing works

Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors

Millan, M. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38982-7 · Cited by 287 · see citing works

Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.

Kapur, S., & Seeman, P. M. (2000) · PubMed · Cited by 285 · see citing works

Dose-Dependent Effects of the Dopamine D1 Receptor Agonists A77636 or SKF81297 On Spatial Working Memory in Aged Monkeys

Cai, J. X., & Arnsten, A. F. T. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36983-6 · Cited by 285 · see citing works

Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs

Grace, A. A., Bunney, B. S., Moore, H. M., & Todd, C. L. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10064-3 · Cited by 284 · see citing works

Important Issues in the Drug Treatment of Schizophrenia

Davis, J. M., Schaffer, C. B., Killian, G. A., Kinard, C. O., & Chan, C. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.1.70 · Cited by 283 · see citing works

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

Tollefson, G. D., Beasley, C. M., Tamura, R., Tran, P. V., & Potvin, J. H. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1248 · Cited by 280 · see citing works

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10600-9 · Cited by 276 · see citing works

Schizophrenia

Kane, J. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340109 · Cited by 273 · see citing works

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

Spohn, H. E., & Strauss, M. E. (1989) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.98.4.367 · Cited by 272 · see citing works

Neurotensin: perchance an endogenous neuroleptic?

Nemeroff, C. B. (1980) · PubMed · Cited by 271 · see citing works

A “Glutamatergic Hypothesis” of Schizophrenia

Deutsch, S. I., Mastropaolo, J. P., Schwartz, B. L., Rosse, R. B., & Morihisa, J. M. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198902000-00001 · Cited by 268 · see citing works

Endocannabinoid signalling in the blood of patients with schizophrenia.

Marchi, N. D., PETROCELLIS, L. D., Orlando, P., Daniele, F., Fezza, F., & Marzo, V. D. (2003) · Lipids in Health and Disease · doi:10.1186/1476-511x-2-5 · Cited by 266 · see citing works

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

Keck, P. E., Buffenstein, A., Ferguson, J. M., Feighner, J. P., Jaffe, W., Harrigan, E. P., & Morrissey, M. R. (1998) · Psychopharmacology · doi:10.1007/s002130050755 · Cited by 265 · see citing works

Dehydroepiandrosterone sulfate improves memory in aging mice

Flood, J. F., & Roberts, E. (1988) · Brain Research · doi:10.1016/0006-8993(88)91116-x · Cited by 259 · see citing works

Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage

Bastianetto, S., Ramassamy, C., Poirier, J., & Quirion, R. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00002-9 · Cited by 257 · see citing works

Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia

Heresco‐Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · The British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255 · see citing works

High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study

Kapur, S., Remington, G. J., Jones, C. E., Wilson, A., DaSilva, J. N., Houle, S., & Zipursky, R. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.7.948 · Cited by 251 · see citing works

Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function

Braunewell, K., & Gundelfinger, E. D. (1999) · Cell and Tissue Research · doi:10.1007/s004410051207 · Cited by 251 · see citing works

Atypical, but Not Typical, Antipsychotic Drugs Increase Cortical Acetylcholine Release without an Effect in the Nucleus Accumbens or Striatum

Ichikawa, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00312-8 · Cited by 248 · see citing works

Antipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors

Corbett, R., Camacho, F., Woods, A. T., Kerman, L. L., Fishkin, R. J., Brooks, K., & Dunn, R. W. (1995) · Psychopharmacology · doi:10.1007/bf02246146 · Cited by 248 · see citing works

Mesolimbic Dopamine D3 Receptors and Use of Antipsychotics in Patients With Schizophrenia

Gurevich, E. V. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830150047009 · Cited by 247 · see citing works

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

GOFF, D. C., Tsai, G. E., Manoach, D. S., & Coyle, J. T. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243 · see citing works

Rapid Release of Antipsychotic Drugs From Dopamine D₂ Receptors: An Explanation for Low Receptor Occupancy and Early Clinical Relapse Upon Withdrawal of Clozapine or Quetiapine

Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237 · see citing works

Neuropsychopharmacology

Ciraulo, D. A. (2003) · JAMA · doi:10.1001/jama.289.23.3175-b · Cited by 232 · see citing works

Glycine Uptake Governs Glycine Site Occupancy at NMDA Receptors of Excitatory Synapses

Berger, A. J., Dieudonné, S., & Ascher, P. (1998) · Journal of Neurophysiology · doi:10.1152/jn.1998.80.6.3336 · Cited by 231 · see citing works

Psychopharmacological Profile of Amisulpride: An Antipsychotic Drug with Presynaptic D2/D3 Dopamine Receptor Antagonist Activity and Limbic Selectivity

Perrault, G., Depoortère, R., Morel, E., Sanger, D. J., & Scatton, B. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36394-3 · Cited by 230 · see citing works

Dehydroepiandrosterone and its sulfate enhance memory retention in mice.

Flood, J. F., Smith, G. E., & Roberts, E. (1988) · Brain Research · doi:10.1016/0006-8993(88)91129-8 · Cited by 227 · see citing works

Glial transporters for glutamate, glycine and GABA I. Glutamate transporters

Gadea, A., & López-Colomé, A. M. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1039 · Cited by 227 · see citing works

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system

Emrich, H. M., Leweke, F. M., & Schneider, U. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00426-1 · Cited by 226 · see citing works

CANNABIS AND SCHIZOPHRENIA

Andréasson, S., Alle­beck, P., Engström, A., & Rydberg, U. S. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91823-5 · Cited by 208 · see citing works

Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy

Markowitz, J. S., Brown, C. S., & Moore, T. R. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17215 · Cited by 208 · see citing works

Serotonergic basis of antipsychotic drug effects in schizophrenia

Lieberman, J. A., Mailman, R. B., Duncan, G., Sikich, L., Chakos, M., Nichols, D. E., & Kraus, J. E. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00187-5 · Cited by 206 · see citing works

Factors influencing relapse in the long-term course of schizophrenia

Ayuso-Gutiérrez, J. L., & Vega, J. M. D. R. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00131-x · Cited by 203 · see citing works

Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release

Gobert, A., Rivet, J., Audinot, V., Newman‐Tancredi, A., Cistarelli, L., & Millan, M. J. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00565-4 · Cited by 203 · see citing works

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

Green, M. F., Marder, S. R., Glynn, S. M., McGurk, S. R., Wirshing, W. C., Wirshing, D. A., Liberman, R. P., & Mintz, J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01370-7 · Cited by 201 · see citing works

Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia

Strous, R. D., Maayan, R., Lapidus, R., Stryjer, R., Lustig, M., Kotler, M., & Weizman, A. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.133 · Cited by 201 · see citing works

The Effects of a Selective D4 Dopamine Receptor Antagonist (L-745,870) in Acutely Psychotic Inpatients With Schizophrenia

Kramer, M. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180085011 · Cited by 199 · see citing works

Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging

Vallée, M., Mayo, W., & Moal, M. L. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00135-7 · Cited by 198 · see citing works

Psychotic Reactions Following Cannabis Use in East Indians

Chopra, G. S. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760070014002 · Cited by 195 · see citing works

Atypical antipsychotic agents: A critical review

Worrel, J. A., Marken, P. A., Beckman, S. E., & Ruehter, V. (2000) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/57.3.238 · Cited by 194 · see citing works

Glutathione and Signal Transduction in the Mammalian CNS

Janáky, R., Ogita, K., Pasqualotto, B. A., Bains, J. S., Oja, S. S., Yoneda, Y., & Shaw, C. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730889.x · Cited by 194 · see citing works

Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice

Roberts, E., Bologa, L., Flood, J. F., & Smith, G. E. (1987) · Brain Research · doi:10.1016/0006-8993(87)90807-9 · Cited by 192 · see citing works

Network interactions in schizophrenia - therapeutic implications.

Carlsson, A., Waters, N., Waters, S., & Carlsson, M. (2000) · Brain research. Brain research reviews · doi:10.1016/s0165-0173(99)00050-8 · Cited by 192 · see citing works

Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions

Schwartz, J.-C. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00043-0 · Cited by 191 · see citing works

Expression of Excitatory Amino Acid Transporter Transcripts in the Thalamus of Subjects With Schizophrenia

Smith, R. E., Haroutunian, V. H., Davis, K. L., & Meador‐Woodruff, J. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1393 · Cited by 190 · see citing works

Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine

Bakshi, V. P., & Geyer, M. A. (1995) · Psychopharmacology · doi:10.1007/bf02246096 · Cited by 189 · see citing works

Striatal Excitatory Amino Acid Transporter Transcript Expression in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder

Mccullumsmith, R., & Meador-Woodruff, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00370-0 · Cited by 189 · see citing works

A PET Study of Dopamine D2 and Serotonin 5-HT2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone

Mamo, D. C., Kapur, S., Shammi, C., Papatheodorou, G. N., Mann, S. W., Therrien, F., & Remington, G. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.818 · Cited by 189 · see citing works

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum

Li, X., Perry, K. W., Wong, D. T., & Bymaster, F. P. (1998) · Psychopharmacology · doi:10.1007/s002130050551 · Cited by 189 · see citing works

Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex

Tanaka, E., & NORTH, R. A. (1993) · Journal of Neurophysiology · doi:10.1152/jn.1993.69.5.1749 · Cited by 187 · see citing works

An integrated view of pathophysiological models of schizophrenia.

Duncan, G., Sheitman, B., & Lieberman, J. (1999) · Brain research. Brain research reviews · doi:10.1016/s0165-0173(99)00002-8 · Cited by 185 · see citing works

An Exploratory Haloperidol-Controlled Dose-Finding Study of Ziprasidone in Hospitalized Patients With Schizophrenia or Schizoaffective Disorder

GOFF, D. C., Posever, T. A., Herz, L. R., Simmons, J., Kletti, N., Lapierre, K. A., Wilner, K. D., Law, C., & Ko, G. N. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00009 · Cited by 183 · see citing works

D-cycloserine added to clozapine for patients with schizophrenia

GOFF, D. C., Tsai, G. E., Manoach, D. S., Flood, J. G., Darby, D., & Coyle, J. T. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182 · see citing works

Neuroactive Neurosteroids as Endogenous Effectors for the Sigma1 (.SIGMA.1) Receptor. Pharmacological Evidence and Therapeutic Opportunities.

Maurice, T., Phan, V.-L., Urani, A., Kamei, H., Noda, Y., & Nabeshima, T. (1999) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.81.125 · Cited by 179 · see citing works

A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia

GOFF, D. C., Henderson, D. C., Evins, A. E., & AMICO, E. T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00367-9 · Cited by 178 · see citing works

Cannabis induced dopamine release: an in-vivo SPECT study

Voruganti, L. N. P., Slomka, P. J., Zabel, P. L., MATTAR, A. G., & Awad, A. G. (2001) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(01)00104-4 · Cited by 172 · see citing works

Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs

Fitzgerald, L., Deutch, A., Gasic, G. P., Heinemann, S., & Nestler, E. J. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-03-02453.1995 · Cited by 171 · see citing works

Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia

Xiberas, X., Martinot, J., Mallet, L., Eric Artiges, A., Loc’h, C., Maziere, B., & Martinot, M. P. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.6.503 · Cited by 169 · see citing works

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

Friedman, J. I., Adler, D. N., Howanitz, E. M., Harvey, P. D., Brenner, G. H., Temporini, H. D., WHITE, L. E., & Parrella, M. J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01342-7 · Cited by 168 · see citing works

Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia

Trân, P. V., Dellva, M. A., Tollefson, G. D., Beasley, C. M., Potvin, J. H., & Kiesler, G. M. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0505 · Cited by 167 · see citing works

Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures

Bologa, L., Sharma, J., & Roberts, E. R. (1987) · Journal of Neuroscience Research · doi:10.1002/jnr.490170305 · Cited by 166 · see citing works

Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice

Shannon, H. E., Rasmussen, K., Bymaster, F. P., Hart, J. C., Peters, S. C., Swedberg, M. D. B., Jeppesen, L., Sheardown, M. J., Sauerberg, P., & Fink‐Jensen, A. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00138-3 · Cited by 165 · see citing works

Clozapine and Haloperidol Modulate N-Methyl-d-aspartate- and Non-N-Methyl-d-aspartate Receptor-Mediated Neurotransmission in Rat Prefrontal Cortical Neurons In Vitro

Arvanov, V. L., Liang, X., Schwartz, J. E., Grossman, S. D., & Wang, R. Y. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37013-2 · Cited by 162 · see citing works

Patient response and resource management: another view of clozapine treatment of schizophrenia

Carpenter, W. T., Conley, R. R., Buchanan, R. W., Breier, A. F., & Tamminga, C. A. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.6.827 · Cited by 161 · see citing works

Cognitive function in schizophrenic patients.

Robinson, D. S., Roberts, D. L., Smith, J. M., Stringfellow, J., Kaplita, S., Seminara, J. A., & Marcus, R. N. (1996) · PubMed · Cited by 159 · see citing works

Positron Emission Tomography Studies on D2 and 5-HT2 Receptor Binding in Risperidone-Treated Schizophrenic Patients

Farde, L., Nyberg, S., Oxenstierna, G., Nakashima, Y., Halldin, C., & ERICSSON, B. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00004 · Cited by 157 · see citing works

Atypical antipsychotics: are some more atypical than others?

Remington, G. J., & Kapur, S. (2000) · Psychopharmacology · doi:10.1007/s002130050017 · Cited by 156 · see citing works

Neuroprotection by propargylamines in Parkinson's disease

Maruyama, W., Akao, Y., Carrillo, M.-C., Kitani, K., Youdium, M. B. H., & Naoi, M. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00221-0 · Cited by 154 · see citing works

Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Enhancement of Delayed-Nonmatch-to-Sample Performance

Hampson, R. E., Rogers, G. A., LYNCH, G. S., & Deadwyler, S. A. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-07-02740.1998 · Cited by 153 · see citing works

Pharmacologic treatment of schizophrenia

Kane, J. M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00059-1 · Cited by 153 · see citing works

Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients

Karlsson, P., Farde, L., Härnryd, C., Sedvall, G., Smith, L. A., & Wiesel, F. ‐. (1995) · Psychopharmacology · doi:10.1007/bf02246068 · Cited by 148 · see citing works

The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease

Friedman, J. I., Adler, D. N., & Davis, K. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00232-2 · Cited by 147 · see citing works

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients

Möller, H., Müller, H., Borison, R. L., Schooler, N. R., & Chouinard, G. (1995) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02191543 · Cited by 147 · see citing works

Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia

Grima, G. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00405-x · Cited by 140 · see citing works

Dr. Meltzer and Mr. Cola Reply

Meltzer, H. Y., & Cola, P. A. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.153 · Cited by 138 · see citing works

Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats

Bubser, M., Keseberg, U., Notz, P., & Schmidt, W. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90288-f · Cited by 138 · see citing works

Pharmacologic strategies for augmenting cognitive performance in schizophrenia

Friedman, J. I., Temporini, H. D., & Davis, K. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00287-x · Cited by 138 · see citing works

Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia

Litman, R. E., Su, T., Potter, W. Z., Hong, W. W., & Pickar, D. (1996) · The British Journal of Psychiatry · doi:10.1192/bjp.168.5.571 · Cited by 137 · see citing works

Quality of life as a predictor for change in disability in MS

Nortvedt, M. W., Riise, T., Myhr, K., & Nyland, H. (2000) · Neurology · doi:10.1212/wnl.55.1.51 · Cited by 134 · see citing works

Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist

Bristow, L. J., Kramer, M. S., Kulagowski, J. J., Patel, S. S., RAGAN, C. I., & Seabrook, G. R. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01066-3 · Cited by 132 · see citing works

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · see citing works

The physiology, signaling, and pharmacology of dopamine receptors

Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763 · see citing works

Identification of a serotonin/glutamate receptor complex implicated in psychosis

González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803 · see citing works

Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial

McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617 · see citing works

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 576 · see citing works

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C. H., Bymaster, F. P., McKinzie, D. L., & Felder, C. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.06091591 · Cited by 563 · see citing works

Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies

Fusar-Poli, P., Smieskova, R., Kempton, M. J., Ho, B. C., Andreasen, N. C., & Borgwardt, S. (2013) · Neuroscience &amp; Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.06.001 · Cited by 512 · see citing works

Transient and Selective Overexpression of Dopamine D2 Receptors in the Striatum Causes Persistent Abnormalities in Prefrontal Cortex Functioning

Kellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520 · see citing works

Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future

Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385 · see citing works

Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors

Bateup, H. S., Santini, E., Shen, W., Birnbaum, S. G., Valjent, E., Surmeier, D. J., Fisone, G., Nestler, E. J., & Greengard, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009874107 · Cited by 356 · see citing works

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

Arranz, M. J., & de León, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 354 · see citing works

Atypical Antipsychotic Agents in the Treatment of Violent Patients With Schizophrenia and Schizoaffective Disorder

KRAKOWSKI, M. I., Czobor, P., Citrome, L., Bark, N. M., & Cooper, T. B. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.622 · Cited by 352 · see citing works

Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia

Demjaha, A., Murray, R. M., McGuire, P. K., Kapur, S., & Howes, O. D. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010144 · Cited by 351 · see citing works

Drug development for CNS disorders: strategies for balancing risk and reducing attrition

Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 334 · see citing works

Psychosis pathways converge via D2High dopamine receptors

Seeman, P. M., Schwarz, J., Chen, J., Szechtman, H., Perreault, M. L., McKnight, G. S., Roder, J., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 328 · see citing works

Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics

Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803522105 · Cited by 320 · see citing works

Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?

Mailman, R., & Murthy, V. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361461 · Cited by 311 · see citing works

A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

Koblan, K. S., KENT, J. M., Hopkins, S. C., Krystal, J. H., Cheng, H., GOLDMAN, R. S., & Loebel, A. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911772 · Cited by 300 · see citing works

A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

Peng, J., Fan, M., An, C., Ni, F., Huang, W., & Luo, J. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13710 · Cited by 291 · see citing works

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity

Kurita, M., Holloway, T. D., García‐Bea, A., Kozlenkov, A., Friedman, A. K., Moreno, J. L., Heshmati, M., Golden, S. A., Kennedy, P., Takahashi, N., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3181 · Cited by 278 · see citing works

Quetiapine versus other atypical antipsychotics for schizophrenia

Komossa, K., Rummel‐Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 261 · see citing works

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems

Meltzer, H. Y., & HUANG, M. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00909-6 · Cited by 248 · see citing works

Cell type–specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs

Bateup, H. S., Svenningsson, P., Kuroiwa, M., Gong, S., Nishi, A., Heintz, N., & Greengard, P. (2008) · Nature Neuroscience · doi:10.1038/nn.2153 · Cited by 233 · see citing works

Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia

Gray, J. A., & Roth, B. L. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm074 · Cited by 225 · see citing works

Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection

Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 223 · see citing works

Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials

Kishi, T., Matsuda, Y., Nakamura, H., & Iwata, N. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.10.011 · Cited by 221 · see citing works

Transient Overexpression of Striatal D2 Receptors Impairs Operant Motivation and Interval Timing

Drew, M. R., Simpson, E., Kellendonk, C., Herzberg, W., Lipatova, O., Fairhurst, S. P., Kandel, E., Malapani, C., & Balsam, P. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1736-07.2007 · Cited by 220 · see citing works

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205 · see citing works

Zebrafish models in neuropsychopharmacology and CNS drug discovery

Khan, K. M., Collier, A. D., Мешалкина, Д. А., Kysil, E. V., Khatsko, S. L., Kolesnikova, T. O., Morzherin, Y. Y., Warnick, J. E., Kalueff, A. V., & Echevarria, D. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13754 · Cited by 206 · see citing works

Ionotropic Glutamate Receptors & CNS Disorders

Bowie, D. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708784083821 · Cited by 200 · see citing works

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cinì, E., Rossi, M., McCormick, P., Corsini, G., Maggio, R., & Scarselli, M. (2018) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 182 · see citing works

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

Zhang, J., & Malhotra, A. K. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.532787 · Cited by 195 · see citing works

Dissociation between In Vivo Occupancy and Functional Antagonism of Dopamine D2 Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models

Natesan, S., Reckless, G. E., Nóbrega, J. N., Fletcher, P. J., & Kapur, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300983 · Cited by 193 · see citing works

Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia

Wonodi, I., & Schwarcz, R. M. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq002 · Cited by 190 · see citing works

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia

Kumra, S., Oberstar, J. V., Sikich, L., Findling, R. L., McClellan, J. M., Vinogradov, S., & Schulz, S. C. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm109 · Cited by 188 · see citing works

Adult Neurogenesis and Psychiatric DisordersPreprint

Kang, E., Wen, Z., Song, H., Christian, K. M., & Ming, G. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019026 · Cited by 187 · see citing works

Clozapine versus other atypical antipsychotics for schizophrenia

Lobos, C. A., Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006633.pub2 · Cited by 187 · see citing works

The pipeline and future of drug development in schizophrenia

Gray, J. A., & Roth, B. L. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002062 · Cited by 181 · see citing works

Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap

Pratt, J. A., Winchester, C. L., Dawson, N., & MORRIS, B. J. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3649 · Cited by 189 · see citing works

Cerebral cortex : principles of operation

Rolls, E. T. (2016) · doi:10.82444/warw.33712699 · Cited by 187 · see citing works

Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis

Zhang, J., Lencz, T., Zhang, R. X., Nitta, M., Maayan, L. A., John, M., Robinson, D. G., Fleischhacker, W. W., Kahn, R. S., Ophoff, R. A., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw058 · Cited by 182 · see citing works

Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies

Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179 · see citing works

Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain

Grajales, D., Ferreira, V., & Valverde, Á. M. (2019) · Cells · doi:10.3390/cells8111336 · Cited by 181 · see citing works

Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia

Nord, M., & Farde, L. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00222.x · Cited by 178 · see citing works

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action

Dedic, N., JONES, P. G., Hopkins, S. C., Lew, R., Shao, L., Campbell, J. E., Spear, K. L., Large, T. H., Campbell, U. C., Hanania, T., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.260281 · Cited by 176 · see citing works

A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia

Lieberman, J. A., Dunbar, G. C., Segreti, A. C., Girgis, R. R., Seoane, F., Beaver, J. S., Duan, N., & Hosford, D. A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.259 · Cited by 176 · see citing works

Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function inNRG1+/−Knock-Outs Compared with Wild-Type Mice

Bjarnadóttir, M., Misner, D., Haverfield-Gross, S., Bruun, S., Helgason, V. G., Stefánsson, H., Sigmundsson, A., Firth, D. R., Nielsen, B., Stefansdottir, R., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4314-06.2007 · Cited by 176 · see citing works

Linking ADHD to the Neural Circuitry of Attention

Mueller, A., Hong, D. S., Shepard, S., & Moore, T. (2017) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2017.03.009 · Cited by 158 · see citing works

Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress‐induced decrease in cell proliferation and BDNF expression in rat hippocampus

Xu, H., Chen, Z., He, J., Haimanot, S., Li, X., Dyck, L. E., & Li, X. (2006) · Hippocampus · doi:10.1002/hipo.20184 · Cited by 173 · see citing works

Clozapine as a Model for Antipsychotic Development

Nucifora, F. C., Mihaljevic, M. M., Lee, B. J., & Sawa, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0552-9 · Cited by 174 · see citing works

The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review

Maletic, V., Eramo, A., Gwin, K., Offord, S. J., & Duffy, R. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00042 · Cited by 171 · see citing works

Psychedelics and schizophrenia

González‐Maeso, J., & Sealfon, S. C. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.005 · Cited by 168 · see citing works

Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors

Guo, D. M., Hillger, J. M., IJzerman, A. P., & Heitman, L. H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21307 · Cited by 167 · see citing works

A Dynamical Systems Hypothesis of Schizophrenia

Loh, M., Rolls, E. T., & Deco, G. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030228 · Cited by 164 · see citing works

Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis

Kusumi, I., Boku, S., & Takahashi, Y. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12242 · Cited by 166 · see citing works

Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis

Zhang, J., Robinson, D. G., Yu, J., Gallego, J. A., Fleischhacker, W. W., Kahn, R. S., Crespo‐Facorro, B., Vázquez-Bourgón, J., Kane, J. M., Malhotra, A. K., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17121363 · Cited by 160 · see citing works

Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity

Kanes, S., Tokarczyk, J., Siegel, S. J., Bilker, W. B., Abel, T. G., & Kelly, M. P. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.09.026 · Cited by 158 · see citing works

Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial

Swartz, M. S., Stroup, T. S., McEvoy, J. P., Thomas, S., Rosenheck, R. A., Keefe, R. S. E., Hsiao, J., & Lieberman, J. A. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.5.500 · Cited by 156 · see citing works

Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study

Yu, H., Yan, H., Wang, L., Li, J., Tan, L., Deng, W., Chen, Q., Yang, G., Zhang, F., Lu, T., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30049-x · Cited by 154 · see citing works

Adverse Effects of Risperidone on Spatial Working Memory in First-Episode Schizophrenia

Reilly, J. L., Harris, M. S. H., Keshavan, M. S., & Sweeney, J. A. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1189 · Cited by 154 · see citing works

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Lai, C.-Y., Scarr, E., Udawela, M., Everall, I., Chen, W. J., & Dean, B. (2016) · World Journal of Psychiatry · doi:10.5498/wjp.v6.i1.102 · Cited by 153 · see citing works

Clinical Assessment and Management of Delirium in the Palliative Care Setting

Bush, S. H., Tierney, S., & Lawlor, P. G. (2017) · Drugs · doi:10.1007/s40265-017-0804-3 · Cited by 153 · see citing works

Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?

Fernø, J., Raeder, M. B., Vik‐Mo, A. O., Skrede, S., Glambek, M., Tronstad, K. J., Breilid, H., Løvlie, R., Berge, R. K., Stansberg, C. T., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500323 · Cited by 152 · see citing works

Randomized Multicenter Investigation of Folate Plus Vitamin B 12 Supplementation in Schizophrenia

Roffman, J. L., Lamberti, J. S., Achtyes, E. D., Macklin, E. A., Galendez, G. C., Raeke, L. H., Silverstein, N. J., Smoller, J. W., Hill, M. B., & GOFF, D. C. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.900 · Cited by 150 · see citing works

Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia

Arnsten, A., Girgis, R. R., Gray, D. L., & Mailman, R. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.028 · Cited by 144 · see citing works

Dopamine D1receptor ligands: Where are we now and where are we going

Zhang, J., Xiong, B., Zhen, X., & Zhang, A. (2008) · Medicinal Research Reviews · doi:10.1002/med.20130 · Cited by 145 · see citing works

The Cytokine Model of Schizophrenia: Emerging Therapeutic Strategies

Girgis, R. R., Kumar, S. S., & Brown, A. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.002 · Cited by 135 · see citing works

G protein-coupled receptors in major psychiatric disorders

Catapano, L. A., & Manji, H. K. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.09.025 · Cited by 131 · see citing works

In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders.

Nikolaus, S., Antke, C., & Müller, H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.009 · Cited by 137 · see citing works

Inhibitory effects of aripiprazole on interferon‐γ‐induced microglial activation via intracellular Ca2+ regulation in vitro

Kato, T. A., Mizoguchi, Y., Monji, A., Horikawa, H., Suzuki, S. O., Seki, Y., Iwaki, T., Hashioka, S., & Kanba, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05435.x · Cited by 122 · see citing works

Schizophrenia: New Pathological Insights and Therapies

Jarskog, L. F., Miyamoto, S., & Lieberman, J. A. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.060904.084114 · Cited by 116 · see citing works

Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target

Wiklund, E. D., Catts, V. S., Catts, S. V., Ng, T. F., Whitaker, N. J., Brown, A. J., & Lutze-Mann, L. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24813 · Cited by 119 · see citing works

Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment.

Weiner, I., & Arad, M. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.004 · Cited by 123 · see citing works

Development of risperidone liposomes for brain targeting through intranasal route

Narayan, R., Singh, M., Ranjan, O. P., Nayak, Y., Garg, S., Shavi, G. V., & Nayak, U. Y. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.08.033 · Cited by 118 · see citing works

Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia

Lodge, D. J., & Grace, A. A. (2008) · Neurotoxicity Research · doi:10.1007/bf03033801 · Cited by 116 · see citing works

The Dopamine D2 Receptor: New Surprises from an Old Friend

Bonci, A., & Hopf, F. W. (2005) · Neuron · doi:10.1016/j.neuron.2005.07.015 · Cited by 115 · see citing works

Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia

Meyer, U., Spoerri, E., Yee, B. K., Schwarz, M., & Feldon, J. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn131 · Cited by 115 · see citing works

Antidepressants- and antipsychotics-induced hepatotoxicity

Todorović, N., Đorđević, J., Pejić, S., Đorđević, N. O., & Pajović, S. B. (2021) · Archives of Toxicology · doi:10.1007/s00204-020-02963-4 · Cited by 119 · see citing works

Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment

Urigüen, L., García-Fuster, M. J., Callado, L. F., Morentín, B., Harpe, R. L., Casadó, V., Lluís, C., Franco, R., Garcı́a-Sevilla, J. A., & Meana, J. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1608-2 · Cited by 115 · see citing works

Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function

Ogino, S., Miyamoto, S., Miyake, N., & Yamaguchi, N. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12088 · Cited by 111 · see citing works

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study

Kerwin, R. W., Millet, B., Herman, E., Bánki, C. M., Lublin, H., Pans, M., Hanssens, L., L'Italien, G. J., McQuade, R. D., & Beuzen, J. N. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.03.002 · Cited by 111 · see citing works

Variants of Dopamine and Serotonin Candidate Genes as Predictors of Response to Risperidone Treatment in First-Episode Schizophrenia

Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kitajima, T., Yoshimura, R., Hashimoto, S., O’Donovan, M. C., Nakamura, J., Ozaki, N., & Iwata, N. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1437 · Cited by 110 · see citing works

Theranostic Biomarkers for Schizophrenia

Perković, M. N., Erjavec, G. N., Štrac, D. Š., Uzun, S., Kozumplik, O., & Pivac, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040733 · Cited by 97 · see citing works

Disrupted sleep and circadian rhythms in schizophrenia and their interaction with dopamine signaling

Ashton, A., & Jagannath, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00636 · Cited by 106 · see citing works

Acute administration of typical and atypical antipsychotics reduces EEG gamma power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in gamma power

Jones, N. C., Reddy, M., Anderson, P., Salzberg, M. R., O'Brien, T. J., & Pinault, D. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000848 · Cited by 103 · see citing works

Atypical Antipsychotics Alter Cholesterol and Fatty Acid Metabolism in Vitro

Canfrán-Duque, A., Casado, M. E., Pastor, Ó., Sánchez-Wandelmer, J., de la Peña, G., Lerma, M., Mariscal, P., Bracher, F., Lasunción, M. A., & Busto, R. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m026948 · Cited by 105 · see citing works

A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory

Smith, J. W., Gastambide, F., Gilmour, G., Dix, S. L., Foss, J., Lloyd, K. G., Malik, N. K., & Tricklebank, M. D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2277-5 · Cited by 106 · see citing works

Therapeutic Drug Monitoring of Common Antipsychotics

Patteet, L., Morrens, M., Maudens, K. E. K., Niemegeers, P., Sabbe, B., & Neels, H. M. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3182708ec5 · Cited by 106 · see citing works

Effects of antipsychotic medications on sleep in schizophrenia

Krystal, A. D., Goforth, H. W., & Roth, T. G. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f39703 · Cited by 105 · see citing works

A Prospective Cohort Study of Antipsychotic Medications in Pregnancy: The First 147 Pregnancies and 100 One Year Old Babies

Kulkarni, J., Worsley, R., Gilbert, H., Gavrilidis, E., Rheenen, T. E. V., Wang, W., McCauley, K., & Fitzgerald, P. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094788 · Cited by 104 · see citing works

Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver

Fernø, J., Vik‐Mo, A. O., Jassim, G., Håvik, B., Berge, K., Skrede, S., Gudbrandsen, O. A., Waage, J. E. R., Lunder, N., Mørk, S. J., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1370-x · Cited by 104 · see citing works

Developing treatments for impaired cognition in schizophrenia

Minzenberg, M., & Carter, C. S. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.017 · Cited by 102 · see citing works

Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway

Girgis, R. R., Javitch, J. A., & Lieberman, J. A. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.40 · Cited by 103 · see citing works

Positive Allosteric Modulation of Metabotropic Glutamate 5 (mGlu5) Receptors Reverses N-Methyl-D-Aspartate Antagonist-Induced Alteration of Neuronal Firing in Prefrontal Cortex

Lecourtier, L., Homayoun, H., Tamagnan, G. D., & Moghaddam, B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.003 · Cited by 101 · see citing works

Therapies for dopaminergic‐induced dyskinesias in parkinson disease

Gottwald, M. D., & Aminoff, M. J. (2011) · Annals of Neurology · doi:10.1002/ana.22423 · Cited by 100 · see citing works

Multi-Target Approach for Drug Discovery against Schizophrenia

Kondej, M., Stępnicki, P., & Kaczor, A. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103105 · Cited by 103 · see citing works

Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics

Meltzer, H. Y. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_4 · Cited by 96 · see citing works

Antibodies to Surface Dopamine-2 Receptor and N-Methyl-D-Aspartate Receptor in the First Episode of Acute Psychosis in Children

Pathmanandavel, K., Starling, J., Merheb, V., Ramanathan, S., Sinmaz, N., Dale, R. C., & Brilot, F. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.07.014 · Cited by 98 · see citing works

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme

Bugarski‐Kirola, D., Iwata, N., Sameljak, S., Reid, C., Blaettler, T., Millar, L., Marques, T. R., Garibaldi, G. M., & Kapur, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30344-3 · Cited by 98 · see citing works

Dopamine D2 and 5-hydroxytryptamine 5-HT2A receptors assemble into functionally interacting heteromers

Borroto‐Escuela, D. O., Romero‐Fernandez, W., Tarakanov, A. O., Marcellino, D. J., Ciruela, F., Agnati, L. F., & Fuxé, K. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.110 · Cited by 98 · see citing works

Treating Schizophrenia Thinking beyond the Choice of Antipsychotic

Lugg, W. (2021) · Journal of Psychology & Psychotherapy · doi:10.35248/2161-0487.21.11.413

Tratamientos para la esquizofrenia. Revisión crítica sobre la farmacología y mecanismos de acción de los antipsicóticos

Tajima, K., Fernández, H., López-Ibor, J. J., Carrasco, J. L., & Díaz-Marsá, M. (2009) · Actas Españolas de Psiquiatría

Pharmacologic treatment of schizophrenia: Current status and future trends

Tandon, R. (2006) · Current Psychosis & Therapeutics Reports · doi:10.1007/bf02629413 · Cited by 2 · see citing works

Novel antipsychotics in schizophrenia

Mortimer, A. M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.315 · Cited by 15 · see citing works

Pharmacologic Treatment of Schizophrenia: What the Future Holds

Tandon, R., & Jibson, M. D. (2001) · CNS Spectrums · doi:10.1017/s1092852900001097 · Cited by 6 · see citing works